AR125270A1 - PHARMACEUTICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 (VARIANTS) - Google Patents

PHARMACEUTICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 (VARIANTS)

Info

Publication number
AR125270A1
AR125270A1 ARP220100816A ARP220100816A AR125270A1 AR 125270 A1 AR125270 A1 AR 125270A1 AR P220100816 A ARP220100816 A AR P220100816A AR P220100816 A ARP220100816 A AR P220100816A AR 125270 A1 AR125270 A1 AR 125270A1
Authority
AR
Argentina
Prior art keywords
seq
agent
component
cov
sars
Prior art date
Application number
ARP220100816A
Other languages
Spanish (es)
Inventor
Olga Vadimovna Zubkova
Tatiana Andreevna Ozharovskaia
Inna Vadimovna Dolzhikova
Olga Popova
Dmitrii Viktorovich Shchebliakov
Daria Mikhailovna Grousova
Alina Shahmirovna Dzharullaeva
Amir Ildarovich Tukhvatulin
Natalia Mikhailovna Tukhvatulina
Dmitrii Nikolaevich Shcherbinin
Ilias Bulatovich Esmagambetov
Elizaveta Alexsandrovna Tokarskaya
Andrei Gennadevich Botikov
Alina Sergeevna Eroxova
Fatima Magometovna Izhaeva
Aleksandr Sergeevich Semikhin
Sergey Vladimirovich Borisevich
Boris Savelievich Naroditsky
Denis Yuryevich Logunov
Aleksandr Leonidovich Gintsburg
Original Assignee
Federal State Budgetary Institution “National Res Centre For Epidemiology And Microbiology Named Aft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Federal State Budgetary Institution “National Res Centre For Epidemiology And Microbiology Named Aft filed Critical Federal State Budgetary Institution “National Res Centre For Epidemiology And Microbiology Named Aft
Priority to ARP220100816A priority Critical patent/AR125270A1/en
Publication of AR125270A1 publication Critical patent/AR125270A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Campo: biotecnología. Sustancia: la invención se refiere a biotecnología, inmunología y virología. Se crea un agente farmacéutico para inducir inmunidad específica contra el virus del síndrome respiratorio agudo severo SARS-CoV-2, que contiene un componente 1 que representa un agente en forma de un vector de expresión basado en el genotipo del adenovirus humano recombinante de serotipo 26 en el cual están eliminadas las regiones E1 y E3, y la región ORF6-Ad26 está reemplazada por ORF6-Ad5, con un casete de expresión integrado seleccionado de SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3, y que contiene un componente 2, que es un agente en forma de un vector de expresión basado en el genoma de la cepa del adenovirus humano recombinante de serotipo 5 en el cual están eliminadas las regiones E1 y E3, con un casete de expresión integrado seleccionado de SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3. También, un agente farmacéutico para inducir inmunidad específica contra el virus del síndrome respiratorio agudo severo SARS-CoV-2, que contiene un componente 1, que es un agente en forma de un vector de expresión basado en el genoma de la cepa del adenovirus humano recombinante de serotipo 26, en el cual están eliminadas las regiones E1 y E3, y la región ORF6- Ad26 está reemplazada por ORF6-Ad5, con un casete de expresión integrado seleccionado de SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3, y que además contiene un componente 2, que es un agente en forma de vector de expresión basado en el genoma de la cepa recombinante del adenovirus de simio de serotipo 25, en el cual están eliminadas las regiones E1 y E3, con un casete de expresión integrado seleccionado de SEQ ID Nº 4, SEQ ID Nº 2, SEQ ID Nº 3. También se crea un agente farmacéutico para inducir inmunidad específica contra el virus del síndrome respiratorio agudo severo SARS-CoV-2, que contiene un componente 1, que representa un agente en la forma de un vector de expresión basado en el genoma de la cepa recombinante del adenovirus de simio de serotipo 25, en el cual están eliminadas las regiones E1 y E3, con un casete de expresión integrado seleccionado de SEQ ID Nº 4, SEQ ID Nº 2, SEQ ID Nº 3, y que además contiene un componente 2, que es un agente en forma de un vector de expresión basado en el genoma de la cepa recombinante humana del adenovirus humano de serotipo 5, en el cual están eliminadas las regiones E1 y E3, con un casete de expresión integrado seleccionado de SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3. Cada agente farmacéutico está en forma líquida o liofilizada, y el componente 1 y el componente 2 están en diferentes envases. Cada agente farmacéutico es utilizado para inducir inmunidad específica contra el virus del síndrome respiratorio agudo severo SARS-CoV-2, en donde los componentes 1 y 2 son utilizados en una cantidad eficaz secuencialmente con un intervalo de no menos de 1 semana. Efecto: la invención proporciona el desarrollo de reacciones de respuesta inmune humoral y celular contra SARS-CoV2, proporcionando así un nivel aumentado de respuesta inmune contra el virus SARS-CoV-2.Field: biotechnology. Substance: The invention relates to biotechnology, immunology and virology. A pharmaceutical agent for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 is created, which contains a component 1 representing an agent in the form of an expression vector based on the genotype of recombinant human adenovirus serotype 26 in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an integrated expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and containing a component 2, which is an agent in the form of an expression vector based on the genome of the recombinant human adenovirus strain serotype 5 in which the E1 and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3. Also, a pharmaceutical agent for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2, which contains a component 1, which is an agent in the form of a expression vector based on the genome of recombinant human adenovirus strain serotype 26, in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an integrated expression cassette selected from SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3, and which also contains a component 2, which is an agent in the form of an expression vector based on the genome of the recombinant strain of simian adenovirus serotype 25, in in which the E1 and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID No. 4, SEQ ID No. 2, SEQ ID No. 3. A pharmaceutical agent for inducing specific immunity against acute respiratory syndrome virus is also created. severe SARS-CoV-2, containing component 1, which represents an agent in the form of an expression vector based on the genome of the recombinant strain of simian adenovirus serotype 25, in which the E1 and E1 regions are deleted E3, with an integrated expression cassette selected from SEQ ID No. 4, SEQ ID No. 2, SEQ ID No. 3, and further containing a component 2, which is an agent in the form of an expression vector based on the genome of the human recombinant strain of human adenovirus serotype 5, in which the E1 and E3 regions are deleted, with an integrated expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. Each pharmaceutical agent is in the form liquid or lyophilized, and component 1 and component 2 are in different packages. Each pharmaceutical agent is used to induce specific immunity against SARS-CoV-2 severe acute respiratory syndrome virus, wherein components 1 and 2 are used in an effective amount sequentially with an interval of not less than 1 week. Effect: The invention provides for the development of humoral and cellular immune response reactions against SARS-CoV2, thus providing an increased level of immune response against the SARS-CoV-2 virus.

ARP220100816A 2022-04-01 2022-04-01 PHARMACEUTICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 (VARIANTS) AR125270A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP220100816A AR125270A1 (en) 2022-04-01 2022-04-01 PHARMACEUTICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 (VARIANTS)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP220100816A AR125270A1 (en) 2022-04-01 2022-04-01 PHARMACEUTICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 (VARIANTS)

Publications (1)

Publication Number Publication Date
AR125270A1 true AR125270A1 (en) 2023-07-05

Family

ID=87551239

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100816A AR125270A1 (en) 2022-04-01 2022-04-01 PHARMACEUTICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 (VARIANTS)

Country Status (1)

Country Link
AR (1) AR125270A1 (en)

Similar Documents

Publication Publication Date Title
Warner et al. Current research for a vaccine against Lassa hemorrhagic fever virus
McKinstry et al. Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2
Taubenberger et al. 1918 Influenza: the mother of all pandemics
Vander Veen et al. Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine
AR121931A1 (en) IMMUNOBIOLOGICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS (VARIANTS)
Van Den Doel et al. Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge
Aréchiga-Ceballos et al. Alphaviral equine encephalomyelitis (Eastern, Western and Venezuelan)
Lázaro-Frías et al. Distinct immunogenicity and efficacy of poxvirus-based vaccine candidates against Ebola virus expressing GP and VP40 proteins
Lukashevich et al. Vaccine platforms to control Lassa fever
Horman et al. The drivers of pathology in zoonotic avian influenza: the interplay between host and pathogen
NO20052149L (en) Polynucleotide vaccine comprising sequence encoding hepatitis C virus protein.
MXPA02011545A (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine.
CL2020000295A1 (en) Factor viii (fviii) gene therapy methods
ZA202202986B (en) Agent for induction of specific immunity against severe acute respiratory syndrome coronavirus (sars-cov-2) in liquid form (versions)
Halbherr et al. Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus
Nygaard et al. Genetic determinants of reovirus pathogenesis in a murine model of respiratory infection
Mussá et al. Swine, human or avian influenza viruses differentially activates porcine dendritic cells cytokine profile
Cai et al. A Lassa virus live-attenuated vaccine candidate based on rearrangement of the intergenic region
Moreno et al. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge
ZA202202322B (en) Expression vector against severe acute respiratory syndrome virus sars-cov-2
Song et al. Virulent and attenuated strains of duck hepatitis A virus elicit discordant innate immune responses in vivo
AR125270A1 (en) PHARMACEUTICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 (VARIANTS)
AR126627A1 (en) AGENT TO INDUCE SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 IN LYOPHILIZED FORM (VARIANTS)
Jiang et al. Recombinant canine adenovirus type 2 expressing rabbit hemorrhagic disease virus VP60 protein provided protection against RHD in rabbits
AR125000A1 (en) EXPRESSION VECTOR FOR THE DEVELOPMENT OF AN IMMUNOBIOLOGICAL AGENT TO INDUCE SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS (VARIANTS)